DOI QR코드

DOI QR Code

Adequacy of Ambulatory Hemodynamic Assessments for Reducing All-Cause Mortality in Individuals With Heart Failure

  • Reza Tabrizchi (Division of BioMedical Sciences, Faculty of Medicine, Memorial University of Newfoundland)
  • 투고 : 2024.04.08
  • 심사 : 2024.09.18
  • 발행 : 2024.10.31

초록

Heart failure (HF) as a syndrome which is normally associated with significant reduction of cardiac output has evolved to include conditions such those of moderate and preserved ejection fraction. While the prevalence of HF in the population is increasing, it is not HF with reduced ejection fraction that is driving the trajectory upward for mortality. There is some evidence to suggest that a better understanding of the pathophysiology, novel pharmacological strategies, devices, as well as remote monitoring of the hemodynamics seem to account for a reduction in the cardiovascular mortality and re-hospitalization in some cohorts with HF. However, the all-cause mortality associated with HF has not been reduced significantly by the current interventions. To explore the potential approaches needed for the strategies and avenues to reduce all-cause mortality in patients with HF, it would be helpful to evaluate the evidence in the literature directed at the care of patients with chronic/acute decompensated HF. It is evident that ambulatory measurements of pressures and volume are pivotal in a better management of HF but unless the interventions extend to an improvement in the renal function, the chances of reducing all-cause mortality seems modest. Therefore, future directions of interventions must not only be directed at close monitoring of pressures and volume simultaneously in HF patients but also at improving renal function. Moreover, it is clear that venous congestion plays a detrimental role in the deterioration of renal function and until measures are in place to reduce it, all-cause mortality will not decrease.

키워드

참고문헌

  1. Savarese G, Lund LH. Global public health burden of heart failure. Card Fail Rev 2017;3:7-11.
  2. Savarese G, Becher PM, Lund LH, Seferovic P, Rosano GM, Coats AJ. Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovasc Res 2023;118:3272-87.
  3. Yan T, Zhu S, Yin X, et al. Burden, trends, and inequalities of heart failure globally, 1990 to 2019: a secondary analysis based on the global burden of disease 2019 study. J Am Heart Assoc 2023;12:e027852.
  4. Redfield MM, Borlaug BA. Heart failure with preserved ejection fraction: a review. JAMA 2023;329:827-38.
  5. Sapna F, Raveena F, Chandio M, et al. Advancements in heart failure management: a comprehensive narrative review of emerging therapies. Cureus 2023;15:e46486.
  6. Westwood M, Almeida AG, Barbato E, et al. Competency-based cardiac imaging for patient-centred care. A statement of the European Society of Cardiology (ESC). With the contribution of the European Association of Cardiovascular Imaging (EACVI), and the support of the Association of Cardiovascular Nursing & Allied Professions (ACNAP), the Association for Acute CardioVascular Care (ACVC), the European Association of Preventive Cardiology (EAPC), the European Association of Percutaneous Cardiovascular Interventions (EAPCI), the European Heart Rhythm Association (EHRA), and the Heart Failure Association (HFA) of the ESC. Eur Heart J Cardiovasc Imaging 2023;24:1415-24.
  7. Tsiouris A, Slaughter MS, Jeyakumar AK, Protos AN. Left ventricular assist devices: yesterday, today, and tomorrow. J Artif Organs. 2024 [Epub ahead of print].
  8. Schrier RW, Abraham WT. Hormones and hemodynamics in heart failure. N Engl J Med 1999;341:577-85.
  9. Anderson JV, Woodruff PW, Bloom SR. The effect of treatment of congestive heart failure on plasma atrial natriuretic peptide concentration: a longitudinal study. Br Heart J 1988;59:207-11.
  10. Hillege HL, Nitsch D, Pfeffer MA, et al. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation 2006;113:671-8.
  11. Heywood JT, Fonarow GC, Costanzo MR, et al. High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure: a report from the ADHERE database. J Card Fail 2007;13:422-30.
  12. Nohria A, Hasselblad V, Stebbins A, et al. Cardiorenal interactions: insights from the ESCAPE trial. J Am Coll Cardiol 2008;51:1268-74.
  13. Testani JM, Coca SG, McCauley BD, Shannon RP, Kimmel SE. Impact of changes in blood pressure during the treatment of acute decompensated heart failure on renal and clinical outcomes. Eur J Heart Fail 2011;13:877-84.
  14. Uthoff H, Breidthardt T, Klima T, et al. Central venous pressure and impaired renal function in patients with acute heart failure. Eur J Heart Fail 2011;13:432-9.
  15. Voors AA, van Veldhuisen DJ, Robertson M, et al. The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT. Eur J Heart Fail 2014;16:426-34.
  16. Aronson D, Burger AJ. The relationship between transient and persistent worsening renal function and mortality in patients with acute decompensated heart failure. J Card Fail 2010;16:541-7.
  17. Waldum B, Westheim AS, Sandvik L, et al. Renal function in outpatients with chronic heart failure. J Card Fail 2010;16:374-80.
  18. Patel UD, Greiner MA, Fonarow GC, Phatak H, Hernandez AF, Curtis LH. Associations between worsening renal function and 30-day outcomes among Medicare beneficiaries hospitalized with heart failure. Am Heart J 2010;160:132-138.e1.
  19. Sato Y, Yoshihisa A, Oikawa M, et al. Prognostic impact of worsening renal function in hospitalized heart failure patients with preserved ejection fraction: a report from the JASPER registry. J Card Fail 2019;25:631-42.
  20. Damman K, van Deursen VM, Navis G, Voors AA, van Veldhuisen DJ, Hillege HL. Increased central venous pressure is associated with impaired renal function and mortality in a broad spectrum of patients with cardiovascular disease. J Am Coll Cardiol 2009;53:582-8.
  21. Damman K, Jaarsma T, Voors AA, et al. Both in- and out-hospital worsening of renal function predict outcome in patients with heart failure: results from the Coordinating Study Evaluating Outcome of Advising and Counseling in Heart Failure (COACH). Eur J Heart Fail 2009;11:847-54. 
  22. Guglin M, Rivero A, Matar F, Garcia M. Renal dysfunction in heart failure is due to congestion but not low output. Clin Cardiol 2011;34:113-6.
  23. Omar HR, Guglin M. Longitudinal BNP follow-up as a marker of treatment response in acute heart failure: relationship with objective markers of decongestion. Int J Cardiol 2016;221:167-70.
  24. Cooper LB, Mentz RJ, Stevens SR, et al. Hemodynamic predictors of heart failure morbidity and mortality: fluid or flow? J Card Fail 2016;22:182-9.
  25. Hanberg JS, Sury K, Wilson FP, et al. Reduced cardiac index is not the dominant driver of renal dysfunction in heart failure. J Am Coll Cardiol 2016;67:2199-208.
  26. Mullens W, Abrahams Z, Francis GS, et al. Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. J Am Coll Cardiol 2009;53:589-96.
  27. Testani JM, Khera AV, St John Sutton MG, et al. Effect of right ventricular function and venous congestion on cardiorenal interactions during the treatment of decompensated heart failure. Am J Cardiol 2010;105:511-6.
  28. Zamora E, Codina P, Aimo A, et al. Trajectories of kidney function in heart failure over a 15-year follow-up: clinical profiling and mortality. JACC Heart Fail 2024;12:849-59.
  29. Stevenson LW, Perloff JK. The limited reliability of physical signs for estimating hemodynamics in chronic heart failure. JAMA 1989;261:884-8.
  30. Nathan AW, Perry SG, Cochrane T, Banim SO, Spurrell RA, Camm AJ. Ambulatory monitoring of pulmonary artery pressure. A preliminary clinical evaluation. Br Heart J 1983;49:33-7.
  31. Gibbs JS, Cunningham D, Shapiro LM, Park A, Poole-Wilson PA, Fox KM. Diurnal variation of pulmonary artery pressure in chronic heart failure. Br Heart J 1989;62:30-5.
  32. Gibbs JS, Keegan J, Wright C, Fox KM, Poole-Wilson PA. Pulmonary artery pressure changes during exercise and daily activities in chronic heart failure. J Am Coll Cardiol 1990;15:52-61.
  33. Drazner MH, Hamilton MA, Fonarow G, Creaser J, Flavell C, Stevenson LW. Relationship between right and left-sided filling pressures in 1000 patients with advanced heart failure. J Heart Lung Transplant 1999;18:1126-32.
  34. Ohlsson A, Bennett T, Nordlander R, Ryden J, Astrom H, Ryden L. Monitoring of pulmonary arterial diastolic pressure through a right ventricular pressure transducer. J Card Fail 1995;1:161-8.
  35. Reynolds DW, Bartelt N, Taepke R, Bennett TD. Measurement of pulmonary artery diastolic pressure from the right ventricle. J Am Coll Cardiol 1995;25:1176-82.
  36. Chuang PP, Wilson RF, Homans DC, et al. Measurement of pulmonary artery diastolic pressure from a right ventricular pressure transducer in patients with heart failure. J Card Fail 1996;2:41-6.
  37. Ohlsson A, Nordlander R, Bennett T, et al. Continuous ambulatory haemodynamic monitoring with an implantable system. The feasibility of a new technique. Eur Heart J 1998;19:174-84.
  38. Ohlsson A, Kubo SH, Steinhaus D, et al. Continuous ambulatory monitoring of absolute right ventricular pressure and mixed venous oxygen saturation in patients with heart failure using an implantable haemodynamic monitor: results of a 1 year multicentre feasibility study. Eur Heart J 2001;22:942-54.
  39. Adamson PB, Magalski A, Braunschweig F, et al. Ongoing right ventricular hemodynamics in heart failure: clinical value of measurements derived from an implantable monitoring system. J Am Coll Cardiol 2003;41:565-71.
  40. Bourge RC, Abraham WT, Adamson PB, et al. Randomized controlled trial of an implantable continuous hemodynamic monitor in patients with advanced heart failure: the COMPASS-HF study. J Am Coll Cardiol 2008;51:1073-9.
  41. Zile MR, Bourge RC, Bennett TD, et al. Application of implantable hemodynamic monitoring in the management of patients with diastolic heart failure: a subgroup analysis of the COMPASS-HF trial. J Card Fail 2008;14:816-23.
  42. Abraham WT, Adamson PB, Bourge RC, et al. Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial. Lancet 2011;377:658-66.
  43. Ritzema J, Troughton R, Melton I, et al. Physician-directed patient self-management of left atrial pressure in advanced chronic heart failure. Circulation 2010;121:1086-95.
  44. Adamson PB, Abraham WT, Bourge RC, et al. Wireless pulmonary artery pressure monitoring guides management to reduce decompensation in heart failure with preserved ejection fraction. Circ Heart Fail 2014;7:935-44.
  45. Abraham WT, Stevenson LW, Bourge RC, et al. Sustained efficacy of pulmonary artery pressure to guide adjustment of chronic heart failure therapy: complete follow-up results from the CHAMPION randomised trial. Lancet 2016;387:453-61.
  46. Varma N, Bourge RC, Stevenson LW, et al. Remote hemodynamic-guided therapy of patients with recurrent heart failure following cardiac resynchronization therapy. J Am Heart Assoc 2021;10:e017619.
  47. Lindenfeld J, Zile MR, Desai AS, et al. Haemodynamic-guided management of heart failure (GUIDE-HF): a randomised controlled trial. Lancet 2021;398:991-1001.
  48. Brugts JJ, Radhoe SP, Clephas PRD, et al. Remote haemodynamic monitoring of pulmonary artery pressures in patients with chronic heart failure (MONITOR-HF): a randomised clinical trial. Lancet 2023;401:2113-23.
  49. Zile MR, Adamson PB, Cho YK, et al. Hemodynamic factors associated with acute decompensated heart failure: part 1--insights into pathophysiology. J Card Fail 2011;17:282-91.
  50. Ivey-Miranda JB, Wetterling F, Gaul R, et al. Changes in inferior vena cava area represent a more sensitive metric than changes in filling pressures during experimental manipulation of intravascular volume and tone. Eur J Heart Fail 2022;24:455-62.
  51. Alvis B, Huston J, Schmeckpeper J, et al. Noninvasive venous waveform analysis correlates with pulmonary capillary wedge pressure and predicts 30-day admission in patients with heart failure undergoing right heart catheterization. J Card Fail 2022;28:1692-702.
  52. Clephas PR, Zwartkruis VW, Malgie J, et al. Pulmonary artery pressure monitoring in chronic heart failure: effects across clinically relevant subgroups in the MONITOR-HF trial. Eur Heart J 2024;45:2954-64.
  53. Lindenfeld J, Costanzo MR, Zile MR, et al. Implantable hemodynamic monitors improve survival in patients with heart failure and reduced ejection fraction. J Am Coll Cardiol 2024;83:682-94.
  54. Codina P, Vicente Gomez JA, Hernandez Guillamet G, et al. Assessing the impact of haemodynamic monitoring with CardioMEMS on heart failure patients: a cost-benefit analysis. ESC Heart Fail 2024;11:1955-62.
  55. Mokri H, Clephas PRD, de Boer RA, van Baal P, Brugts JJ, Rutten-van Molken MP. Cost-effectiveness of remote haemodynamic monitoring by an implantable pulmonary artery pressure monitoring sensor (CardioMEMS-HF system) in chronic heart failure in the Netherlands. Eur J Heart Fail 2024;26:1189-98.
  56. Yu CM, Wang L, Chau E, et al. Intrathoracic impedance monitoring in patients with heart failure: correlation with fluid status and feasibility of early warning preceding hospitalization. Circulation 2005;112:841-8.
  57. Vanderheyden M, Houben R, Verstreken S, et al. Continuous monitoring of intrathoracic impedance and right ventricular pressures in patients with heart failure. Circ Heart Fail 2010;3:370-7.
  58. Vollmann D, Nagele H, Schauerte P, et al. Clinical utility of intrathoracic impedance monitoring to alert patients with an implanted device of deteriorating chronic heart failure. Eur Heart J 2007;28:1835-40.
  59. Conraads VM, Tavazzi L, Santini M, et al. Sensitivity and positive predictive value of implantable intrathoracic impedance monitoring as a predictor of heart failure hospitalizations: the SENSE-HF trial. Eur Heart J 2011;32:2266-73.
  60. Heist EK, Herre JM, Binkley PF, et al. Analysis of different device-based intrathoracic impedance vectors for detection of heart failure events (from the Detect Fluid Early from Intrathoracic Impedance Monitoring study). Am J Cardiol 2014;114:1249-56.
  61. Abraham WT, Compton S, Haas G, et al. Intrathoracic impedance vs daily weight monitoring for predicting worsening heart failure events: results of the Fluid Accumulation Status Trial (FAST). Congest Heart Fail 2011;17:51-5.
  62. Maier SK, Paule S, Jung W, et al. Evaluation of thoracic impedance trends for implant-based remote monitoring in heart failure patients - Results from the (J-)HomeCARE-II Study. J Electrocardiol 2019;53:100-8.
  63. van Veldhuisen DJ, Braunschweig F, Conraads V, et al. Intrathoracic impedance monitoring, audible patient alerts, and outcome in patients with heart failure. Circulation 2011;124:1719-26.
  64. Domenichini G, Rahneva T, Diab IG, et al. The lung impedance monitoring in treatment of chronic heart failure (the LIMIT-CHF study). Europace 2016;18:428-35.
  65. Luthje L, Vollmann D, Seegers J, Sohns C, Hasenfuss G, Zabel M. A randomized study of remote monitoring and fluid monitoring for the management of patients with implanted cardiac arrhythmia devices. Europace 2015;17:1276-81.
  66. Bohm M, Drexler H, Oswald H, et al. Fluid status telemedicine alerts for heart failure: a randomized controlled trial. Eur Heart J 2016;37:3154-63.
  67. Wintrich J, Pavlicek V, Brachmann J, et al. Remote monitoring with appropriate reaction to alerts was associated with improved outcomes in chronic heart failure: results from the OptiLink HF study. Circ Arrhythm Electrophysiol 2021;14:e008693.
  68. Wintrich J, Pavlicek V, Brachmann J, et al. Impedance-based remote monitoring in patients with heart failure and concomitant chronic kidney disease. ESC Heart Fail 2023;10:3011-8.
  69. Grinstead WC, Francis MJ, Marks GF, Tawa CB, Zoghbi WA, Young JB. Discontinuation of chronic diuretic therapy in stable congestive heart failure secondary to coronary artery disease or to idiopathic dilated cardiomyopathy. Am J Cardiol 1994;73:881-6.
  70. Testani JM, Brisco MA, Turner JM, et al. Loop diuretic efficiency: a metric of diuretic responsiveness with prognostic importance in acute decompensated heart failure. Circ Heart Fail 2014;7:261-70.
  71. Eder M, Griffin M, Moreno-Villagomez J, et al. The importance of forward flow and venous congestion in diuretic response in acute heart failure: insights from the ESCAPE trial. Int J Cardiol 2023;381:57-61.
  72. Ma G, Ma X, Wang G, Teng W, Hui X. Effects of tolvaptan add-on therapy in patients with acute heart failure: meta-analysis on randomised controlled trials. BMJ Open 2019;9:e025537.
  73. Wang L, Zhang Q, Liu M, et al. Tolvaptan in reversing worsening acute heart failure: A systematic review and meta-analysis. J Int Med Res 2019;47:5414-25.
  74. Luo X, Jin Q, Wu Y. Tolvaptan add-on therapy in patients with acute heart failure: A systematic review and meta-analysis. Pharmacol Res Perspect 2020;8:e00614.
  75. Cao H, Rao X, Jia J, Yan T, Li D. Effects of sodium-glucose cotransporter-2 inhibitors on kidney, cardiovascular, and safety outcomes in patients with advanced chronic kidney disease: a systematic review and meta-analysis of randomized controlled trials. Acta Diabetol 2023;60:325-35.
  76. Carvalho PEP, Veiga TMA, Simoes E Silva AC, et al. Cardiovascular and renal effects of SGLT2 inhibitor initiation in acute heart failure: a meta-analysis of randomized controlled trials. Clin Res Cardiol 2023;112:1044-55.